Oleg Pohotsky - Tekla Life Independent Chairman of the Board of Trustees
| HQL Stock | USD 13.02 0.03 0.23% |
Chairman
Mr. Oleg M. Pohotsky is Independent Trustee of HQ Life Sciences Investors. Mr. Pohotsky serves as Chairman of the Board of Trustees of each Fund and also serves as Chairman of each Fund Valuation Committee and serves on each Fund Audit Committee. He has over 45 years of cumulative board experience in the full range of organization types publiclytraded, privatelyheld, venturebacked and nonprofit. He has also served as a director of a healthcare services company listed on the Nasdaq NMS where he was a member of the audit committee. In his various directorships he has also served on investment, compensation, personnel and executive committees. His career spanned over twenty years in the investment industry, both as an investment banker and as a VC and private equity investor, and included serving as chairman of the valuation and fairness opinion committee of a NYSEmember firm. Mr. Pohotsky also currently serves on the Board of Directors of Avangardco Investments Holdings, an LSElisted agribusiness enterprise based in Ukraine, on the board of directors of the New America High Income Fund, Inc., a closed end fund investing in high yield securities on a leveraged basis and on the Board of Advisors of Kaufman Co., LLC, a Bostonbased boutique investment banking firm, and is affiliated with GovernanceMetrics International, Inc. as a Senior Advisor. He provides each Fund with valuable experience in valuation and the financial industry since 2012.
| Age | 73 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hql.html |
Tekla Life Management Efficiency
Tekla Life's management efficiency ratios could be used to measure how well Tekla Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| R Chadwick | Flaherty and Crumrine | 44 | |
| Joseph Harvey | Cohen Steers Reit | 57 | |
| Terence Toth | Nuveen Preferred and | 62 | |
| Steven Pruchansky | John Hancock Financial | 76 | |
| William Park | Eaton Vance Risk | 74 | |
| R Chadwick | Flaherty Crumrine Preferred | 44 | |
| Richard Cavanagh | Blackrock Muniyield | 75 | |
| William Park | Eaton Vance Tax | 74 | |
| Hassell McClellan | John Hancock Financial | 75 | |
| William Park | Eaton Vance Tax | 74 | |
| William Park | Eaton Vance Tax | 74 | |
| Karen Robards | Blackrock Muniyield | 71 | |
| James Oates | John Hancock Financial | 74 | |
| Robert Steers | Cohen And Steers | 67 | |
| Terence Toth | Nuveen California Select | 62 | |
| James Bowen | First Trust Intermediate | 65 | |
| Robert Steers | Cohen Steers Reit | 67 | |
Management Performance
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 |
Tekla Life Sciences Leadership Team
Elected by the shareholders, the Tekla Life's board of directors comprises two types of representatives: Tekla Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Life's management team and ensure that shareholders' interests are well served. Tekla Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Dr MS, President Officer | ||
| Peter Branner, Chief Officer | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, Principal Executive Officer and President Trustee and Member of Valuation Committee | ||
| Rakesh Jain, Independent Trustee |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 21.43 % | ||||
| Operating Margin | (0.66) % | ||||
| Current Valuation | 364.52 M | ||||
| Shares Outstanding | 28.06 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 34.47 % | ||||
| Number Of Shares Shorted | 96.46 K | ||||
| Price To Earning | 2.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.